HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Despotis, G. J. Articles by Lappas, D. G. Search for Related Content PubMed PubMed Citation Articles by Despotis, G. J. Articles by Lappas, D. G.

J Thorac Cardiovasc Surg 1995;110:46-54
© 1995 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation

St. Louis, Mo.

Supported in part by a research grant from Medtronic Hemotec.

Received for publication August 2, 1994. Accepted for publication Nov. 15, 1994. Address for reprints: George Despotis, MD, Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, Box 8054, Washington University School of Medicine, 660 South Euclid Ave., St. Louis, MO 63110

Abstract

A whole blood hemostasis system (Hepcon) provides both activated clotting time and accurate whole blood heparin concentration measurements via an automated protamine titration method. This study was designed to prospectively evaluate the impact of heparin and protamine administration using this system on the incidence and treatment of bleeding after cardiopulmonary bypass. Two hundred fifty-four patients requiring cardiopulmonary bypass were enrolled in this prospective study over a 7-month period. Patients treated with antifibrinolytic agents (aprotinin,-aminocaproic or tranexamic acid) were excluded. Patients were randomly assigned to either a control (n = 127) or intervention (n = 127) group. For control patients, the anticoagulation protocol consisted of an initial fixed dose of 250 U/kg of heparin, and additional 5000 U heparin doses were administered if the activated clotting time was less than 480 seconds. Heparin was neutralized with an initial fixed dose of protamine (0.8 mg protamine per milligram total heparin). For the intervention group, an initial dose of heparin was based on an automated heparin dose-response assay. Additional heparin doses were administered if the heparin concentration was less than the reference concentration or for an activated clotting time less than 480 seconds. The protamine dose was based on the residual heparin concentration. Treatment of excessive bleeding after cardiopulmonary bypass was based on an algorithm using point-of-care testing with whole blood prothrombin time, activated partial thromboplastin time, heparinase activated clotting time, and platelet count. No differences between the two treatment groups were identified in reference to demographic factors, preoperative anticoagulant medications, preoperative coagulation data, number of reoperations, or combined procedures and duration of cardiopulmonary bypass. Indirect evidence for coagulation factor consumption was demonstrated in control patients by more prolonged whole blood prothrombin time and activated partial thromboplastin time values after cardiopulmonary bypass when compared with values obtained in the intervention group. Patients in the intervention cohort received greater doses of heparin (intervention: 612±147, control: 462±114 U/kg, p < 0.0001) and had lower protamine to heparin ratios (intervention: 0.70±0.64, control: 0.94±0.21, p = 0.0001) compared with control patients. Patients in the intervention cohort received significantly fewer platelet (intervention: 1.7±3.6 U, control: 3.7±6.7 U, p = 0.003), plasma (intervention: 0.4±1.3 U, control: 1.4±2.5 U, p = 0.0001), and cryoprecipitate units (intervention: 0.0±0.0 U, control: 0.2±1.2 U, p = 0.04) during the perioperative interval than control patients. A greater percentage of control patients required hemostatic transfusion (intervention: 17%, control: 33%, p = 0.005) during the perioperative period. Control patients also required longer operative times for closure (intervention: 92±32, control: 102±34, p = 0.02). Chest tube drainage in the first 24 postoperative hours was not different between treatment groups (intervention: 839±377, control: 924±520, p = 0.14). In summary, maintenance of patient-specific heparin concentrations, based on heparin activated clotting time response, during cardiopulmonary bypass led to greater heparin doses and lower doses of protamine relative to heparin dose. Higher porcine heparin doses were not associated with excessive postoperative bleeding. By facilitating maintenance of a therapeutic heparin concentration and determination of an appropriate protamine dose, point-of-care testing using the Hepcon system was associated with reduced blood product utilization. This difference may, in part, be due to better preservation of the coagulation system. (J THORACCARDIOVASCSURG1995;110:46-54)

This article has been cited by other articles:

				J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				E. B. Mossad, S. Machado, and J. Apostolakis Bleeding following deep hypothermia and circulatory arrest in children. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46. [Abstract] [PDF]

				C. C. Harle and J. M. Murkin Another bleeding heart: perioperative heparin management revisited/Un autre coeur qui saigne : une reevaluation de l'anticoagulation a l'heparine Can J Anesth, February 1, 2007; 54(2): 97 - 102. [Full Text] [PDF]

				R. Taneja and D. C. Cheng Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372. [Full Text] [PDF]

				B. Tremey, B. Szekely, S. Schlumberger, D. Francois, N. Liu, K. Sievert, and M. Fischler Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron(R) low range activated clotting time (ACT-LR) Br. J. Anaesth., October 1, 2006; 97(4): 453 - 459. [Abstract] [Full Text] [PDF]

				P. Federico, F. Annalisa, C. Giuseppe, D. S. Francesco, T. Lucia, and Z. Alberto Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration Perfusion, September 1, 2006; 21(5): 285 - 290. [Abstract] [PDF]

				K. A. A. Aziz, O. Masood, J. A. Hoschtitzky, and A. Ronald Does use of the Hepcon(R) point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 469 - 482. [Abstract] [Full Text] [PDF]

				C. W. Hogue Jr, C. A. Palin, R. Kailasam, J. S. Lawton, A. Nassief, V. G. Davila-Roman, B. Thomas, and R. Damiano C-reactive protein levels and atrial fibrillation after cardiac surgery in women. Ann. Thorac. Surg., July 1, 2006; 82(1): 97 - 102. [Abstract] [Full Text] [PDF]

				A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF]

				V. G. Nielsen Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann. Thorac. Surg., May 1, 2006; 81(5): 1720 - 1727. [Abstract] [Full Text] [PDF]

				M.S. Avidan, J.H. Levy, H. van Aken, R.O. Feneck, R.D. Latimer, E. Ott, E. Martin, D.E. Birnbaum, L.J. Bonfiglio, D.K. Kajdasz, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 107 - 113. [Abstract] [Full Text] [PDF]

				S. A Spinler, A. K Wittkowsky, E. A Nutescu, and M. A Smythe Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin Ann. Pharmacother., July 1, 2005; 39(7): 1275 - 1285. [Abstract] [Full Text] [PDF]

				M.N. Shuhaibar, M. Hargrove, M.H. Millat, A. O'Donnell, and T. Aherne How much heparin do we really need to go on pump? A rethink of current practices Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 947 - 950. [Abstract] [Full Text] [PDF]

				M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]

				B. S. Donahue Factor V Leiden and Perioperative Risk Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634. [Abstract] [Full Text] [PDF]

				R. I. P. Dornan Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome Br. J. Anaesth., May 1, 2004; 92(5): 748 - 754. [Abstract] [Full Text] [PDF]

				P. K. Neema, P. K. Sinha, and R. C. Rathod Activated Clotting Time During Cardiopulmonary Bypass: Is Repetition Necessary During Open Heart Surgery? Asian Cardiovasc Thorac Ann, March 1, 2004; 12(1): 47 - 52. [Abstract] [Full Text] [PDF]

				M. S. Avidan, E. L. Alcock, J. Da Fonseca, J. Ponte, J. B. Desai, G. J. Despotis, and B. J. Hunt Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery Br. J. Anaesth., February 1, 2004; 92(2): 178 - 186. [Abstract] [Full Text] [PDF]

				P. J. Santrach Devices for Monitoring Heparin and Protamine in the Operating Room Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 379 - 385. [Abstract] [PDF]

				W. C. Oliver Jr Overview of Heparin and Protamine Management and Dosing Regimens in Pediatric Cardiac Surgical Patients Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 387 - 410. [Abstract] [PDF]

				A. Gruber and S. R. Hanson Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates Blood, August 1, 2003; 102(3): 953 - 955. [Abstract] [Full Text] [PDF]

				W. L. Chandler and T. Velan Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass Blood, June 1, 2003; 101(11): 4355 - 4362. [Abstract] [Full Text] [PDF]

				P. Svenarud and E. Ovrum Clinical Effects of Different Protamine Doses After Cardiopulmonary Bypass Asian Cardiovasc Thorac Ann, June 1, 2002; 10(2): 119 - 123. [Abstract] [Full Text] [PDF]

				C. P. R. Walker and D. Royston Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies Br. J. Anaesth., June 1, 2002; 88(6): 848 - 863. [Abstract] [Full Text] [PDF]

				D. M. Moskowitz, S. I. Perelman, K. M. Cousineau, J. J. Klein, A. Shander, E. J. Margolis, S. A. Katz, H. L. Bennett, N. E. Lebowitz, and M. A. Ergin Multidisciplinary management of a Jehovah's Witness patient for the removal of a renal cell carcinoma extending into the right atrium: [La prise en charge multidisciplinaire d'un patient Temoin de Jehovah pour le retrait d'un hypernephrome s'etendant dans l'oreillette droite] Can J Anesth, April 1, 2002; 49(4): 402 - 408. [Abstract] [Full Text] [PDF]

				G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]

				M. Codispoti, C. A. Ludlam, D. Simpson, and P. S. Mankad Individualized heparin and protamine management in infants and children undergoing cardiac operations Ann. Thorac. Surg., March 1, 2001; 71(3): 922 - 927. [Abstract] [Full Text] [PDF]

				W. Dietrich, S. Braun, M. Spannagl, and J. A. Richter Low Preoperative Antithrombin Activity Causes Reduced Response to Heparin in Adult but not in Infant Cardiac-Surgical Patients Anesth. Analg., January 1, 2001; 92(1): 66 - 71. [Abstract] [Full Text] [PDF]

				G. J. Despotis and L. T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32. [Abstract] [Full Text] [PDF]

				J. H. Lemmer Jr Clinical experience in coronary bypass surgery for abciximab-treated patients Ann. Thorac. Surg., August 1, 2000; 70(2): S33 - 37. [Abstract] [Full Text] [PDF]

				E. W. Muriithi, P. R. Belcher, S. P. Day, V. C. Menys, and D. J. Wheatley Heparin-induced platelet dysfunction and cardiopulmonary bypass Ann. Thorac. Surg., June 1, 2000; 69(6): 1827 - 1832. [Abstract] [Full Text] [PDF]

				R. Saleem, M. Bigham, E. Spitznagel, and G. J. Despotis The Effect of Epsilon-Aminocaproic Acid on HemoSTATUS(R) and Kaolin-Activated Clotting Time Measurements Anesth. Analg., June 1, 2000; 90(6): 1281 - 1285. [Abstract] [Full Text] [PDF]

				M. Codispoti and P. S Mankad Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice Perfusion, May 1, 2000; 15(3): 191 - 201. [Abstract] [PDF]

				C. J. East, F. Clements, J. Mathew, and T. F. Slaughter Antiphospholipid Syndrome and Cardiac Surgery: Management of Anticoagulation in Two Patients Anesth. Analg., May 1, 2000; 90(5): 1098 - 1101. [Full Text] [PDF]

				J. H. Lemmer Jr, M. T. Metzdorff, A. H. Krause Jr, M. A. Martin, J. E. Okies, and J. G. Hill Emergency coronary artery bypass graft surgery in abciximab-treated patients Ann. Thorac. Surg., January 1, 2000; 69(1): 90 - 95. [Abstract] [Full Text] [PDF]

				R. Berryessa, R. Wiencek, J. Jacobson, D. Hollingshead, K. Farmer, and G. Cahill Practical techniques Vacuum-assisted venous return in pediatric cardiopulmonary bypass Perfusion, January 1, 2000; 15(1): 63 - 67. [Abstract] [PDF]

				O. Shigeta, H. Kojima, Y. Hiramatsu, T. Jikuya, Y. Terada, N. Atsumi, Y. Sakakibara, T. Nagasawa, and T. Mitsui LOW-DOSE PROTAMINE BASED ON HEPARIN-PROTAMINE TITRATION METHOD REDUCES PLATELET DYSFUNCTION AFTER CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., August 1, 1999; 118(2): 354 - 360. [Abstract] [Full Text] [PDF]

				F. M LaDuca, M. L Zucker, and C. E Walker Assessing heparin neutralization following cardiac surgery: sensitivity of thrombin time-based assays versus protamine titration methods Perfusion, May 1, 1999; 14(3): 181 - 187. [Abstract] [PDF]

				N. Ramamurthy, N. Baliga, J. A. Wahr, U. Schaller, V. C. Yang, and M. E. Meyerhoff Improved protamine-sensitive membrane electrode for monitoring heparin concentrations in whole blood via protamine titration§ Clin. Chem., March 1, 1998; 44(3): 606 - 613. [Abstract] [Full Text] [PDF]

				G. J. Despotis, J. H. Joist, and L. T. Goodnough Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes Clin. Chem., September 1, 1997; 43(9): 1684 - 1696. [Abstract] [Full Text] [PDF]

				G. J. Despotis, J. H. Joist, L. T. Goodnough, S. A. Santoro, and E. Spitznagel WHOLE BLOOD HEPARIN CONCENTRATION MEASUREMENTS BY AUTOMATED PROTAMINE TITRATION AGREE WITH PLASMA ANTI-XA MEASUREMENTS J. Thorac. Cardiovasc. Surg., March 1, 1997; 113(3): 611 - 613. [Full Text]

				G. S. Aldea, M. Doursounian, P. O'Gara, P. Treanor, O. M. Shapira, H. L. Lazar, and R. J. Shemin Heparin-Bonded Circuits With a Reduced Anticoagulation Protocol in Primary CABG: A Prospective, Randomized Study Ann. Thorac. Surg., August 1, 1996; 62(2): 410 - 418. [Abstract] [Full Text]

				J.-F. Hardy, S. Belisle, D. Robitaille, J. Perrault, M. Roy, and L. Gagnon MEASUREMENT OF HEPARIN CONCENTRATION IN WHOLE BLOOD WITH THE HEPCON/HMS DEVICE DOES NOT AGREE WITH LABORATORY DETERMINATION OF PLASMA HEPARIN CONCENTRATION USING A CHROMOGENIC SUBSTRATE FOR ACTIVATED FACTOR X J. Thorac. Cardiovasc. Surg., July 1, 1996; 112(1): 154 - 161. [Abstract] [Full Text]

				M. J. Moulton, L. L. Creswell, M. E. Mackey, J. L. Cox, and M. Rosenbloom REEXPLORATION FOR BLEEDING IS A RISK FACTOR FOR ADVERSE OUTCOMES AFTER CARDIAC OPERATIONS J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1037 - 1046. [Abstract] [Full Text]

				G. J. Despotis, A. L. Alsoufiev, E. Spitznagel, L. T. Goodnough, and D. G. Lappas Response of Kaolin ACT to Heparin: Evaluation With an Automated Assay and Higher Heparin Doses Ann. Thorac. Surg., March 1, 1996; 61(3): 795 - 799. [Abstract] [Full Text]

				P. Martin, S. Bannan, and S. S. Ashraf Individualized patient heparinization and protamine reversal J. Thorac. Cardiovasc. Surg., February 1, 1996; 111(2): 493 - 493. [Full Text]